
Christian M Zechmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6441069/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Detection Rate of ¹⁸ F-Fluorethylcholine-PET/CT in relation to PSA Value in PCA Patients Referred with Biochemical Relapse. Contrast Media and Molecular Imaging, 2020, 2020, 1-8.	0.8	1
2	Increased microcirculation detected by dynamic contrastâ€enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma. British Journal of Haematology, 2016, 174, 127-135.	2.5	25
3	Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. European Radiology, 2016, 26, 1404-1411.	4.5	28
4	Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to 68Ga-DOTATOC PET. European Journal of Radiology, 2015, 84, 1593-1600.	2.6	21
5	Imaging for Prostate Cancer. Current Radiology Reports, 2015, 3, 1.	1.4	0
6	Comparison of gadobenate dimeglumine-enhanced breast MRI and gadopentetate dimeglumine-enhanced breast MRI with mammography and ultrasound for the detection of breast cancer. Journal of Magnetic Resonance Imaging, 2014, 39, 1272-1286.	3.4	7
7	Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 11-20.	6.4	817
8	Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1280-1292.	6.4	319
9	Automated vs. Manual Pattern Recognition of 3D 1H MRSI Data of Patients with Prostate Cancer. Academic Radiology, 2012, 19, 675-684.	2.5	5
10	Parametric Histogram Analysis of Dynamic Contrast-enhanced MRI in Multiple Myeloma. Academic Radiology, 2012, 19, 100-108.	2.5	11
11	Reproducibility of 3D ¹ H MR spectroscopic imaging of the prostate at 1.5T. Journal of Magnetic Resonance Imaging, 2012, 35, 166-173.	3.4	15
12	Anterior Cruciate Ligament Reconstruction Using Patellar Tendon Versus Hamstring Tendon: A Prospective Comparative Study With 9-Year Follow-Up. Arthroscopy - Journal of Arthroscopic and Related Surgery, 2011, 27, 653-665.	2.7	109
13	Respiratory-Induced Prostate Motion. Strahlentherapie Und Onkologie, 2011, 187, 426-432.	2.0	18
14	Multicenter, Double-Blind, Randomized, Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for Breast MR Imaging (DETECT Trial). Radiology, 2011, 258, 396-408.	7.3	55
15	Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging of bone marrow in healthy individuals. Acta Radiologica, 2011, 52, 324-330.	1.1	36
16	Comparison of Peripheral Zone and Central Gland Volume in Patients Undergoing Intensity-Modulated Radiotherapy. Journal of Computer Assisted Tomography, 2010, 34, 739-745.	0.9	5
17	Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Importance of Whole-Body versus Spinal MR Imaging. Radiology, 2009, 252, 477-485.	7.3	113
18	Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 tesla. Acta Radiologica, 2009, 50, 521-530.	1.1	24

#	Article	IF	CITATIONS
19	Estimating Kinetic Parameter Maps From Dynamic Contrast-Enhanced MRI Using Spatial Prior Knowledge. IEEE Transactions on Medical Imaging, 2009, 28, 1534-1547.	8.9	44
20	3D Reconstructions of the Cerebral Ventricles and Volume Quantification in Children with Brain Malformations. Academic Radiology, 2009, 16, 610-617.	2.5	24
21	Changes of prostate gland volume with and without androgen deprivation after intensity modulated radiotherapy – A follow-up study. Radiotherapy and Oncology, 2009, 90, 408-412.	0.6	13
22	Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma. International Journal of Cancer, 2008, 122, 2871-2875.	5.1	18
23	Pharmacokinetic Analysis of Malignant Pleural Mesothelioma—Initial Results of Tumor Microcirculation and its Correlation to Microvessel Density (CD-34). Academic Radiology, 2008, 15, 563-570.	2.5	44
24	Where is the primary tumour?. Lancet, The, 2007, 370, 1800.	13.7	2
25	Impact of Stroma on the Growth, Microcirculation, Metabolism of Experimental Prostate Tumors. Neoplasia, 2007, 9, 57-67.	5.3	35
26	Automated estimation of tumor probability in prostate magnetic resonance spectroscopic imaging: Pattern recognition vs quantification. Magnetic Resonance in Medicine, 2007, 57, 150-159.	3.0	43
27	Dynamic Contrast-Enhanced MRI of Malignant Pleural Mesothelioma. Chest, 2006, 129, 1570-1576.	0.8	78